Advanced Filters
noise
Found 645 clinical trials
B Bryson Katona, MD

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

18 years of age All Phase N/A
S Shailendra Singh, MD

Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients …

18 years of age All Phase N/A
T Toni Basinski, MS

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.

18 years of age All Phase N/A
X XianJun Yu, M.D., Ph.D.

A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection

This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from clinically-annotated individuals.

40 - 75 years of age All Phase N/A
J Juan Du, PhD

CtDNA-guided Maintenance Therapy in Pancreatic Cancer

This study aims to conduct a large-scale prospective clinical trial to evaluate the efficacy and safety of capecitabine monotherapy as maintenance treatment following standard adjuvant chemotherapy (gemcitabine plus capecitabine) in patients with resectable pancreatic cancer, and to analyze whether ctDNA-MRD testing can guide the selection of postoperative maintenance therapy.

18 years of age All Phase N/A
M Martin PETIT, MD

Effectiveness of the Transversus Abdominis Plane Block Associated With Opioid Spinal Anesthesia on Analgesia After Cephalic Duodenopancreatectomy

Duodenopancreatectomy is a major, risky surgery that causes significant post-operative pain. Optimizing perioperative analgesia remains a challenge, and requires multimodal management, notably involving locoregional analgesic techniques. The thoracic epidural helps reduce perioperative pain, as well as certain postoperative complications. However, epidural analgesia is not without effects, and the data remains …

18 years of age All Phase N/A
L Leonardo Henry Umberto Eusebi, MD

Role of Exosomes in Pancreatic Cancer Progression

The present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their association with disease stage, to evaluate their potential use as predictive and diagnostic markers for this tumor of difficult early diagnosis and …

18 years of age All Phase N/A
X XianJun Yu, M.D., Ph.D.

Multi-omics Model for Pancreatic Cancer Screening Using cfDNA

This is a prospective case-control study, aiming at developing a cell free DNA (cfDNA) multi-omics precise diagnostic model for screening of pancreatic cancer.

18 - 75 years of age All Phase N/A
S Simon E Grutzmeier, MD

Pharmacotyping of Pancreatic Patient-derived Organoids

EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. The organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.

18 years of age All Phase N/A
C ChenLeiWen

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.

18 - 75 years of age All Phase N/A

Simplify language using AI